Wren Laboratories, a leader in molecular diagnostics, is proud to announce that its breakthrough liquid biopsy test, PROSTest鈩�, has been approved by the New York State Department of Health Clinical Laboratory Evaluation Program (NYSDOH-CLEP).
Wren Laboratories announced executive leadership for commercial operations and market expansion. Dr. Abdel Halim is appointed CEO and CSO. Troy Tremaine Appointed to CCO, Dr. Eva Szarek Head of Marketing, and Melissa Ferone director of quality. Expansion includes AI-driven mRNA liquid biopsy genomic assays for biopharma and diagnostics.
Wren Laboratories is pleased to announce the addition of Dr. Mark Harman, MD, MBA, MS, BCMAS, as a Clinical Consultant for the 10-year-old molecular diagnostic company.
The presentation will focus on the use of mRNA in Liquid Biopsies as a platform for precision diagnostics
Licensing agreement with Kindstar Globalgene Technology will more than double Wren NETest distribution within first year
Blood-based molecular NET cancer test delivers accuracy and specificity levels unsurpassed by other diagnostic methods
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right